Key AACE-Supported Legislation Reintroduced in U.S. House of Representatives

Friday, January 6, 2017 2:25 pm EST

Dateline:

WASHINGTON, D.C.
"After six years of AACE advocacy and efforts by AACE members, our colleagues in the diabetes community and dedicated congressional supporters, we’re confident that the hard work is paying off and this crucial piece of patient care legislation is on the cusp of becoming a reality"

The National Clinical Care Commission Act (H.R. 309), a long-standing legislative priority for AACE members and the diabetes community, appears to be on a fast track for action by the 115th U.S. Congress, with the bill being reintroduced January 5 in the House of Representatives by co-sponsors Rep. Pete Olson (R-22-TX) and Rep. Dave Loebsack (D-2-IA).

The legislation was approved by the House during the 114th Congress and was sent to the Senate for consideration, which adjourned for the year before voting on the bill. Because the legislation was approved by the House in the last Congress it has been cleared again for swift House consideration.  The legislation will also soon be reintroduced in the Senate by co-sponsors Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME).

The National Clinical Care Commission Act calls for the creation of a public/private collaborative of the country’s foremost researchers, clinical healthcare professionals and patient advocates who will collectively evaluate existing federally administered diabetes, metabolic and autoimmune disease initiatives in order to improve the coordination and implementation of these programs and improve patient care. The commission will make recommendations to the Secretary of Health and Human Services and the Congress.

Since the bill was first introduced in the House during the 112th Congress, the prevalence of diabetes has continued to surge: According to the Centers for Disease Control and Prevention (CDC), diabetes afflicts one in every nine adult Americans, and an additional 86 million Americans have prediabetes. The total annual cost of diabetes in the U.S. is estimated at $245 billion.

“After six years of AACE advocacy and efforts by AACE members, our colleagues in the diabetes community and dedicated congressional supporters, we’re confident that the hard work is paying off and this crucial piece of patient care legislation is on the cusp of becoming a reality,” said Dr. Howard M. Lando, FACP, FACE, Chair of AACE’S Legislative and Regulatory Committee.

###